Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Will your baby get a hep B vaccine? What RFK panel's ruling means. - 2EU foreign ministers commemorate Russian massacre in Bucha
- 3Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- 4NMG signs new graphite supply deal with Canadian Government
- 5I thought I knew the night sky, but what I saw from the Canary Islands left me speechless
- Novo Nordisk cuts Wegovy price in South Africa for a second time
- Hyundai Is Keeping the i30 Alive While America Keeps Losing Cars Like It
- Support Your Body: A Manual for Smart dieting and Sustenance
- Disney's latest short film 'Versa' tackles a difficult subject: Pregnancy loss. It's resonating with viewers.
- Grasping Wrongdoings and Crimes: A Correlation
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- A Manual for Well known Western television Series
- 5 State of the art Advancements in Computer generated Simulation
- NASA's Artemis II launch leaves Americans in awe: 'We're going back to the frickin' moon!'
